2011 Press Releases

• B. Braun Renal Therapies Division Announces Enhanced Offerings for Hemodialysis System
  Bethlehem, PA — November 15, 2011 — Improving staff efficiency and providing greater safety for renal therapy patients, B. Braun Medical Inc. (B. Braun) announced today the availability of an 1100g Solcart B Cartridge for use with the Dialog+ Hemodialysis System, the leading method used in the treatment of patients with kidney failure.
  more >>

• Safety to the Power of Three: B. Braun Medical Inc. Announces Introcan Safety^® 3 Closed IV Catheter
  Bethlehem, PA — October 19, 2011 — Expanding its offering of passive safety devices to protect both clinicians and patients from needlestick injuries (NSIs), B. Braun Medical Inc. (B. Braun) recently announced that the U.S. Food and Drug Administration (FDA) granted 510(k) clearance of the company’s Introcan Safety^® 3 Closed IV Catheter, the next generation of B. Braun’s Introcan Safety^® IV Catheter. B. Braun made the announcement during the Association for Vascular Access 2011 Annual Scientific Meeting in San Jose, Calif., in early October.
  more >>

• B. Braun Advocating for Patient Care with RAadvantages.com
  Bethlehem, PA — October 14, 2011 — "The patient's end result should be the primary goal," says Dr. Laura Clark, while making the point that, "Regional Anesthesia (RA) needs to be worked into every hospital system for the betterment of the patient." As the Director of Acute Pain and Regional Anesthesia at the University of Louisville School of Medicine, Dr. Clark attests that RA can reduce the cost of surgical stays while meeting the primary goal of improving the overall patient experience. She recognizes that faulty perceptions about costs and schedule restraints create "a need to educate surgeons and administrators."
  more >>

• Contained Medication System Now Keeping Hospitals Compliant With Latest Legislation
  Bethlehem, PA — August 8, 2011 — In its efforts to further advance best practices with the continuous improvement of safety, B. Braun Medical Inc. (B. Braun) announced today that its OnGuard™ Contained Medication System can help increase institution and new legislation compliance regarding the protection of healthcare workers from exposure to hazardous drugs.
  more >>

• B. Braun and CME America Partner to Provide BodyGuard^® Infusion Pumps
  Bethlehem, PA — July 18, 2011 — In an effort to expand its offerings for infusion therapy in both the acute care hospital and outpatient markets, with an initial focus on home infusion, B. Braun Medical Inc. (B. Braun) announced today an exclusive alliance with CME America to distribute the BodyGuard^® line of electronic infusion pumps.
  more >>

• B. Braun Renal Therapies Division Announces Availability of Advanced Apheresis Therapy System
  Bethlehem, PA — July 14, 2011 — The Renal Therapies Division of B. Braun Medical Inc. (B. Braun) announced today the availability of the Plasmat^™ Futura System for H.E.L.P.^® LDL Apheresis therapy. This addition to B. Braun's existing H.E.L.P.^® therapy provides a more easy-to-use system for clinicians to administer the most effective care to patients with severe hypercholesterolemia.
  more >>

• B. Braun Acquires Patent for Enhanced Wireless Communication Between Medical Devices and Hospital Information Management Systems
  Bethlehem, PA — July 12, 2011 — B. Braun Medical Inc. (B. Braun) announced today that it has acquired US patent 7,933,780, which was issued April 26, 2011, and two pending applications, providing the Company patent rights related to enhanced communication between medical devices and hospital information management systems through wireless communication.
  more >>

• B. Braun Medical Inc. Named Best Company to Work For
  Bethlehem, PA — June 15, 2011 — B. Braun Medical Inc. (B. Braun) is part of one of the fastest growing medical technology corporations in the world — it's also one of the Best Companies to Work For, according to Medical Device and Diagnostic Industry (MD+DI) magazine. One of just 10 medical device companies named to MD+DI's 2011 list, B. Braun "must be doing something right."
  more >>

• FDA Approves Ceftazidime 1g and 2g for use in B. Braun's DUPLEX^® System
  Bethlehem, PA — June 13, 2011 — The U.S. Food and Drug Administration (FDA) today approved B. Braun Medical Inc.'s (B. Braun) application for 1g and 2g Ceftazidime for Injection USP and Dextrose Injection USP in the DUPLEX^® Drug Delivery System.
  more >>

• B. Braun Obtains Permanent Injunction
  Bethlehem, PA — May 4, 2011 — Germany-based medical device manufacturer B. Braun Melsungen AG and its U.S. subsidiary B. Braun Medical Inc. (B. Braun) announced today that the company succeeded in obtaining a permanent injunction in its patent infringement case against Japan's Terumo Corporation and its U.S. subsidiary Terumo Medical Corporation.
  more >>

• B. Braun Offers Wound Patients a New "Over-the-Counter" Wound Management Gel - Prontosan^®
  Bethlehem, PA — January 10, 2011 — In its continued effort to advance best practices in wound care management, B. Braun Medical Inc. (B. Braun) announced today that Prontosan^® Wound Management Gel with PHMB (Polyhexanide), a product used in the healthcare setting for cleaning wounds as well as moistening and lubricating absorbent wound dressings, is now available for over-the-counter (OTC) use. The U.S. Food and Drug Administration (FDA) granted 510(k) clearance for Prontosan^® Wound Management Gel for OTC use in November 2010.
  more >>